⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons

Official Title: Phase II Study of Ixabepilone in Patients With Metastatic Breast Cancer and a Prospective Evaluation of Its Effects on the Ultrastructure of Neurons

Study ID: NCT00627978

Interventions

ixabepilone

Study Description

Brief Summary: Primary Objectives * Assess ultrastructure changes in dermal myelinated nerves of patients who receive ixabepilone chemotherapy * Detailed characterization of peripheral neuropathy in patients who receive ixabepilone Secondary Objectives * Clinical benefit rate * Time to progression ( TTP) * Toxicity * Exploratory studies: * Relation of MDR 1 and TRKA polymorphisms to evolution of ultrastructural neurologic changes observed in neurons. * Relation of NGF, IL8, and IL10 to the development of clinical symptoms and ultrastructural changes in neurons.

Detailed Description: Eligible patient population: * Stage 4 breast cancer * Resolution from toxicity of prior therapy to ≤ CTC grade 1 ( except alopecia) * No limit on prior number of therapies to treat cancer * Adequate organ function * Life expectancy greater than 3 months Treatment: ixabepilone 40 mg/m2 Q3w over 3 hours Evaluation on Study: I. Efficacy evaluation: * Baseline CT chest, abdomen and pelvis and bone scan within 4 weeks of starting therapy * Evaluation of disease every 2 cycles of chemotherapy * Ongoing toxicity evaluation using NCI CTC 3. II. Neurological evaluation: * Detailed neurologic exam using Neuropathy Assessment Instrument (represents a standard neurological exam) * Serum NGF, IL 8,10, prior to starting therapy and prior to each cycle of ixabepilone * DNA for assessment of TRK A and MDR1 polymorphisms * Punch biopsy of skin prior to starting therapy and after every 2 cycles. Laboratory evaluation of peripheral nerve biopsies will be conducted at Rockefeller University under the direction of Dr. Carlson in Dr. Strickland's Lab.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Weill Medical College of Cornell University, New York, New York, United States

Contact Details

Name: Linda Vahdat, MD

Affiliation: Weill Medical College of Cornell University

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: